Article Text

Download PDFPDF
Association of CXC Chemokine Receptor Type 4 Expression and Clinicopathologic Features in Human Vulvar Cancer
  1. Takaya Shiozaki, MD*,
  2. Tsutomu Tabata, MD*,
  3. Nei Ma, PhD,
  4. Takaharu Yamawaki, MD,
  5. Takashi Motohashi, MD*,
  6. Eiji Kondo, MD*,
  7. Kouji Tanida, MD*,
  8. Toshiharu Okugawa, MD* and
  9. Tomoaki Ikeda, MD*
  1. *Departments of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu;
  2. Faculty of Health Science, Suzuka University of Medical Science, Suzuka; and
  3. Departments of Obstetrics and Gynecology, Ise Red Cross Hospital, Funae, Japan.
  1. Address correspondence and reprint requests to Takaya Shiozaki, MD, Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507, Japan. E-mail:


Objective Although CXC chemokine receptor type 4 (CXCR4) is known to be expressed in various solid tumors and plays an integral role in cancer invasion and metastasis, expression of CXCR4 in human vulvar cancer has not yet been investigated. We examined distribution and expression of this chemokine receptor in specimens of invasive and noninvasive human vulvar neoplasms to elucidate its clinical significance.

Methods Study patients were 38 consecutive patients (31 with primary vulvar cancers and 7 with intraepithelial neoplasms) treated at one of our hospitals. Sections of all specimens were evaluated for CXCR4 expression by means of immunohistochemistry. Relations between CXCR4 expression and clinicopathologic features including prognosis were investigated.

Results None of the 7 vulvar intraepithelial lesions expressed CXCR4. Of the 31 invasive vulvar tumor samples examined, 19 (61%) stained positively for CXCR4; 15 (68%) of 22 squamous cell carcinomas and 2 (29%) of 7 Paget tumors were CXCR4 positive. The difference in expression between invasive cancers and intraepithelial neoplasms was significant (P = 0.003). FIGO (International Federation of Gynecology and Obstetrics) stage III–IV cancers, in comparison to FIGO stage I–II cancers, were more likely to be positive for CXCR4 (82% vs 50%, P = 0.08). In terms of disease-free survival, prognosis of cancers that expressed CXCR4 was poorer than that of CXCR4-negative cancers (P = 0.013), but in terms of disease-specific survival, prognosis did not differ significantly between CXCR4-positive and -negative cancers (P = 0.111).

Conclusions More than half of invasive squamous cell vulvar cancers can be expected to express CXCR4, and CXCR4 expression correlates with poor disease prognosis.

  • Vulvar cancer
  • CXCR4
  • Prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Support is from departmental sources only.

  • The authors declare no conflicts of interest.